nAChR-IN-1_product_DataBase

Bioactivity	nAChR-IN-1 (2,2,6,6-Tetramethylpiperidin-4-yl heptanoate) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research[1].
Invitro	nAChR-IN-1 (100 nM) inhibits nAChR with inhibition rate of 90% in Xenovus oocytes, and suppresses AChR subtypes (mouse muscle-type (α1β1εδ) nAChR, three different pairwise combinations of rat neuronal alpha and beta subunits (α3β4, α4β2, and α3β2), and α7 homomeric neuronal nAChR) with IC50s (area) of 390, 1.2, 110, 75, 440, 460, 430, 2.7, 1.0, 1.4, and 18.3 nM, respectively, based on the decrease in the net charge of the ACh response[1].
In Vivo	nAChR-IN-1 (20 mg/kg; s.c.; single dose) improves nicotine-induced hypomotility and hypothermia in a time-dependent manner in mice[1]. Animal Model:
Name	nAChR-IN-1
CAS	849461-90-1
Formula	C16H31NO2
Molar Mass	269.42
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Papke RL, et, al. Compositions et methodes d'inhibition selective des recepteurs nicotiniques de l'acetylcholine. WO2005032479A2

PeptideDB